JP2014517282A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517282A5
JP2014517282A5 JP2014510754A JP2014510754A JP2014517282A5 JP 2014517282 A5 JP2014517282 A5 JP 2014517282A5 JP 2014510754 A JP2014510754 A JP 2014510754A JP 2014510754 A JP2014510754 A JP 2014510754A JP 2014517282 A5 JP2014517282 A5 JP 2014517282A5
Authority
JP
Japan
Prior art keywords
bladder cancer
subject
prognosis
sample
sample value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517282A (ja
Filing date
Publication date
Priority claimed from EP11166558A external-priority patent/EP2524928A1/en
Application filed filed Critical
Publication of JP2014517282A publication Critical patent/JP2014517282A/ja
Publication of JP2014517282A5 publication Critical patent/JP2014517282A5/ja
Pending legal-status Critical Current

Links

JP2014510754A 2011-05-18 2012-05-11 膀胱癌におけるｒｂｍ３ Pending JP2014517282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161487341P 2011-05-18 2011-05-18
EP11166558.4 2011-05-18
EP11166558A EP2524928A1 (en) 2011-05-18 2011-05-18 RBM3 in bladder cancer
US61/487,341 2011-05-18
PCT/EP2012/058826 WO2012156330A1 (en) 2011-05-18 2012-05-11 Rbm3 in bladder cancer

Publications (2)

Publication Number Publication Date
JP2014517282A JP2014517282A (ja) 2014-07-17
JP2014517282A5 true JP2014517282A5 (https=) 2015-06-25

Family

ID=44358146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510754A Pending JP2014517282A (ja) 2011-05-18 2012-05-11 膀胱癌におけるｒｂｍ３

Country Status (6)

Country Link
US (4) US8728739B2 (https=)
EP (2) EP2524928A1 (https=)
JP (1) JP2014517282A (https=)
AU (1) AU2012257798A1 (https=)
CA (1) CA2834653A1 (https=)
WO (1) WO2012156330A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
EP2746768A1 (en) * 2012-12-20 2014-06-25 Atlas Antibodies AB Podxl in bladder cancer
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
CN110195109A (zh) * 2019-07-03 2019-09-03 北京太东生物科技有限公司 Rbm46作为睾丸肿瘤标志物的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007084485A2 (en) 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
EP2520935A3 (en) * 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2090890A1 (en) 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
CN105224827B (zh) * 2008-07-01 2019-12-24 小利兰·斯坦福大学托管委员会 用于发展ivf治疗协议的分析数据的计算机系统和存储介质
EP2396657B1 (en) 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis

Similar Documents

Publication Publication Date Title
Bissolati et al. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer
Hutterer et al. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma
Todenhöfer et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients
Shin et al. Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion
Labiche et al. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma
Elsawaf et al. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour
Köhler et al. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
Uhlig et al. Contrast enhancement on cone-beam breast-CT for discrimination of breast cancer immunohistochemical subtypes
JP2014517282A5 (https=)
Kan et al. The prognosis of subsequent surgical treatment in patients with sarcomatoid carcinoma in the liver: a retrospective study
Choi et al. Impact of lymph node dissection in radical cystectomy for bladder cancer: how many vs how far?
De-Colle et al. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: inter-patient and intra-patient heterogeneity
Pannier et al. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer
Sun et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy
Park et al. ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma
Seo et al. Epidemiologic study of human epidermal growth factor receptor 2 expression in advanced/metastatic gastric cancer: an assessment of human epidermal growth factor receptor 2 status in tumor tissue samples of gastric and gastro-esophageal junction cancer
CN117999363A (zh) 用于无细胞的dna表观遗传的胃肠道癌检测以及治疗的组成物和方法
Okamoto et al. Risk factors for complications following lateral pelvic lymph node dissection for rectal cancer
Keruakous et al. The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy
Nadoshan et al. Prognostic value of lymph node ratios in node positive rectal cancer treated with preoperative chemoradiation
JP2016508219A5 (https=)
Harris et al. Quest for the ideal cancer biomarker: an update on progress in capture and characterization of circulating tumor cells
Sharir et al. Lymph node assessment and lymphadenectomy in bladder cancer
Sano et al. Lung metastasis of Ta bladder cancer: a case report and literature review
Urquhart et al. Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer